(17E)-17-hydroxyimino-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: (17E)-17-hydroxyimino-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-3-ol
• 化学式: C₁₉H₃₁NO₂
• 分子量: 305.5
• InChiKey: CWINRPKWTQFSKW-LVZFUZTISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  52.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• NEW MEDICAL USE
  申请人：Umecrine Cognition AB

  公开号：EP4079307A1

  公开（公告）日：2022-10-26

  The present invention is directed to the compound golexanolone or a pharmaceutically acceptable salt thereof, for use in the treatment of fatigue or cognitive impairment, or a combination thereof, in a non-cirrhotic patient with a chronic liver disease, wherein the patient has a serum level of allopregnanolone which is 0.03 ng/ml or higher.

  本发明涉及化合物戈来孕诺龙或其药学上可接受的盐，用于治疗慢性肝病非肝硬化患者的疲劳或认知障碍，或其组合，其中患者血清中异丙孕诺龙的水平为 0.03 纳克/毫升或更高。
• [EN] PHARMACEUTICAL FORMULATION OF 3α-ETHYNYL-3β-HYDROXYANDROSTAN-17-ONE OXIME<br/>[FR] FORMULATION PHARMACEUTIQUE DE 3α-ÉTHYNYLE-3β-HYDROXYANDROSTAN-17-ONE OXIME
  申请人：UMECRINE COGNITION AB

  公开号：WO2019102040A1

  公开（公告）日：2019-05-31

  The present invention is directed to a novel pharmaceutical formulation comprising 3α-ethynyl-3β- hydroxyandrostan-17-one oxime in an amount of 0.1-10 % by weight of the total weight of the composition; and a vehicle comprising (a) 45-100 % of a monoester; (b) optionally up to 51 % of a diester; and (c) optionally up to about 10 % of a triester. Also claimed is a method for the treatment of medical conditions such as hypersomnia and hepathic encephalopathy by the use of a pharmaceutical formulation as claimed.